SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
April 09, 2020
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew appoints Anne-Francoise Nesmes as Chief Financial
Officer
9 April 2020
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
business, is pleased to announce that Anne-Francoise Nesmes has
been appointed as the Company's new Chief Financial Officer
('CFO'). Anne-Francoise will join Smith+Nephew by 3 August 2020,
once her current commitments have concluded, when she will also be
appointed to the Board as an Executive Director.
Anne-Francoise Nesmes is currently CFO of Merlin Entertainments Ltd
('Merlin'), the world's second-largest visitor attraction operator,
a position she has held since August 2016. Merlin was a constituent
of the FTSE 250 before being acquired by private equity in November
2019. Anne-Francoise is also a Non-Executive Director of
Compass Group PLC.
Prior to Merlin, Anne-Francoise was CFO of FTSE 250 specialist
animal health company Dechra Pharmaceuticals PLC (2013-2016), and
held a variety of increasingly senior roles at GlaxoSmithKline plc
in the UK and overseas (1997-2013), including Senior Vice President
of Finance for the £3.5 billion revenue vaccines
business.
Anne-Francoise qualified as a Chartered Management Accountant and
has an MBA from Henley Management College. She has dual French
and British citizenship.
Roland Diggelmann, Chief Executive Smith+Nephew,
commented:
"Anne-Francoise is an exceptional finance leader who has
demonstrated her effectiveness supporting ambitious strategic,
investment and efficiency programmes in both healthcare and other
sectors. I am excited that she is joining
Smith+Nephew."
Anne-Francoise Nesmes commented:
"This is a wonderful opportunity to join a major global healthcare
company with a strong heritage and exciting long-term prospects. I
look forward to working with Roland and the team, and supporting
their ambitious vision for Smith+Nephew."
As previously announced, Graham Baker will step down as CFO and
leave Smith+Nephew for a new opportunity on 30 April 2020. Ian
Melling, Senior Vice President Group Finance, will serve as interim
CFO from that date until Anne-Francoise joins. Graham will stand
down as a Director after the Annual General Meeting to be held at
2:00pm today.
No further disclosure obligations arise under paragraphs (1) to (6)
of LR 9.6.13 R of the Financial Conduct Authority's Listing Rules
in respect of these appointments.
Remuneration
Anne-Francoise Nesmes will be paid in accordance with the
Remuneration Policy, which will be presented to shareholders for
approval later today, and as set out in the 2019 Annual
Report:
●
She will receive a base salary of
£580,000 per annum;
●
She will participate in the Annual
Bonus Plan with a maximum opportunity of 215% of base salary, of
which 50% will be paid in cash and 50% will be paid in shares
deferred for three years. For 2020, this will be pro-rated for
length of time served;
●
She will participate in the
Performance Share Programme with a maximum opportunity of 275% of
base salary;
●
The Company will pay cash in lieu of a
pension of 12% of salary per annum;
●
She will receive standard benefits,
which are not materially different in nature or value relative to
the incumbent CFO;
●
Her notice period will not be less
than six months from her and not less than 12 months from the
Company.
Enquiries
Investors
Andrew
Swift
+44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
Susan Gilchrist / Ayesha
Bharmal
+44 (0) 20 7404 5959 Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 17,500+ employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Advanced Wound Management and Sports
Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.1 billion in 2019.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
◊ Trademark of Smith+Nephew. Certain marks registered US
Patent and Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: April
09, 2020
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jul 2024 to Jul 2024
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jul 2023 to Jul 2024